Ono Pharmaceutical Co., Ltd.

DB:ON4 Stock Report

Market Cap: €4.6b

Ono Pharmaceutical Valuation

Is ON4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ON4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ON4 (€10) is trading below our estimate of fair value (€24.42)

Significantly Below Fair Value: ON4 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ON4?

Key metric: As ON4 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ON4. This is calculated by dividing ON4's market cap by their current earnings.
What is ON4's PE Ratio?
PE Ratio7.8x
EarningsJP¥95.13b
Market CapJP¥745.66b

Price to Earnings Ratio vs Peers

How does ON4's PE Ratio compare to its peers?

The above table shows the PE ratio for ON4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.5x
DMP Dermapharm Holding
22.5x17.0%€2.0b
MRK Merck KGaA
22.2x11.1%€59.9b
PSG PharmaSGP Holding
15.3x13.6%€287.8m
2FJ0 Pierrel
29.9xn/a€92.8m
ON4 Ono Pharmaceutical
7.8x-6.8%€745.7b

Price-To-Earnings vs Peers: ON4 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (22.5x).

Price to Earnings Ratio vs Industry

How does ON4's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
ON4 7.8xIndustry Avg. 19.5xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ON4 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is ON4's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ON4 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.8x
Fair PE Ratio12.6x

Price-To-Earnings vs Fair Ratio: ON4 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the estimated Fair Price-To-Earnings Ratio (12.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ON4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.00
€12.79
+27.9%
34.6%€27.14€8.70n/a13
Dec ’25€10.70
€12.96
+21.1%
33.9%€27.25€8.73n/a13
Nov ’25€11.60
€12.98
+11.9%
31.0%€26.36€10.86n/a13
Oct ’25€11.90
€13.59
+14.2%
30.5%€27.20€11.20n/a13
Sep ’25€13.10
€13.75
+5.0%
29.5%€27.05€11.14n/a13
Aug ’25€13.00
€14.22
+9.4%
27.6%€26.94€11.10n/a13
Jul ’25€12.50
€14.54
+16.3%
26.8%€25.36€11.03n/a12
Jun ’25€13.10
€15.22
+16.2%
32.9%€30.30€11.14n/a12
May ’25€13.20
€16.12
+22.1%
29.3%€30.71€11.88n/a12
Apr ’25€14.80
€16.62
+12.3%
30.8%€32.15€11.19n/a12
Mar ’25€15.00
€16.47
+9.8%
30.7%€31.67€11.03n/a12
Feb ’25€15.50
€17.11
+10.4%
28.5%€32.51€12.58n/a13
Jan ’25€15.60
€17.49
+12.1%
27.6%€32.91€13.37n/a13
Dec ’24€16.40
€17.01
+3.7%
27.4%€31.91€12.96€10.7013
Nov ’24€15.60
€17.14
+9.9%
24.5%€29.98€13.17€11.6013
Oct ’24€17.80
€18.17
+2.1%
26.4%€30.26€13.29€11.9011
Sep ’24€17.10
€17.93
+4.8%
24.7%€30.12€13.23€13.1013
Aug ’24€16.80
€18.26
+8.7%
25.1%€30.85€13.55€13.0013
Jul ’24€16.20
€18.30
+13.0%
24.7%€30.36€13.97€12.5012
Jun ’24€17.10
€20.26
+18.5%
22.6%€31.35€14.67€13.1013
May ’24€17.90
€21.21
+18.5%
19.9%€31.31€16.65€13.2013
Apr ’24€18.50
€22.47
+21.5%
18.9%€32.85€17.47€14.8013
Mar ’24€18.70
€22.81
+22.0%
18.3%€32.71€17.40€15.0013
Feb ’24€19.70
€23.38
+18.7%
13.7%€28.97€19.08€15.5012
Jan ’24€21.40
€26.46
+23.6%
15.0%€31.46€18.75€15.6013
Dec ’23€24.00
€25.97
+8.2%
15.0%€31.00€18.48€16.4013

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ono Pharmaceutical Co., Ltd. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research